Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis-Reference-Cited by-同舟云学术

Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis

Published:2021-09-07 Issue:3 Volume:195 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hwang Jonwei¹^ORCID,Singh Naina²,Braniecki Marylee³,Gok Yavuz Betul²,Tsoukas Maria M.⁴,Quigley John G.²^ORCID

Affiliation:

1. University of Illinois College of Medicine Chicago ILUSA

2. Department of Hematology/Oncology University of Illinois at ChicagoChicago ILUSA

3. Department of Pathology University of Illinois at ChicagoChicago ILUSA

4. Department of Dermatology University of Illinois at Chicago Chicago IL USA

Funder

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17715

Reference15 articles.

1. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

2. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

3. Altering Chemosensitivity by Modulating Translation Elongation

4. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

5. Rapid Turnover of c-FLIPshort Is Determined by Its Unique C-terminal Tail

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homoharringtonine is a transdermal granular permeation enhancer;Biochemical and Biophysical Research Communications;2022-08